Differential changes in maternal proinflammatory IL6 plasma levels as a putatively surrogate marker of candidacy and clinical utility during mid- and late pregnancy hyperglycemia: interventional impact of clinical pharmacist on maternal and neonatal outcomes in a randomized clinical trial

Background/methods: The impact of clinical pharmacist on undiagnosed pregnancy hyperglycemia (PHG) in mid- and late- pregnancy as a major preventable cause of maternal and neonatal (M/N) complications is investigated. This longitudinal randomized controlled study of changes in plasma levels of predictive/prognostic/diagnostic biomarkers of oxytocin, thrombospondin, MCP1, IL6, MIF, insulin and LAR and undesirable M/N pregnancy outcomes in women with/out PHG (pregnancy normoglycemia; PNG) following the implementation of clinical pharmacist interventions were investigated. Results: A total of 68 PHG (36 intervention vs. 32 non-intervention) vs. 21 PNG participants were enrolled at 20-28 weeks and followed up till delivery. BMI of intervention PHG (unlike non-intervention) was greater (p=0.036) compared to PNG's. LAR and insulin, oxytocin, thrombospondin1, adiponectin and MCP1 plasma levels and their differences between 2nd and 3rd pregnancy trimesters lacked discrepancies in participants. Both PHG groups in mid pregnancy had substantially greater HbA1c %, FPG and IL6 levels vs. PNG, while PHG non-intervention' leptin was greater than PNG's. In late pregnancy, greater SBP, IL6 and MIF levels between either PHG groups vs. PNG's were observed. Unlike PHG non-intervention and PNG; IL6 level in PHG intervention group decreased (-2.54 +/- 6.61; vs. non-intervention PHG's 4.26 +/- 5.28; p<0.001 and vs. PNG's 2.30 +/- 4.27; p=0.023). None of the assessed M/N outcomes was found of differential significance between any of the three study groups. Conclusions: Proinflammatory IL6 as a robust and generalizable cardiometabolic risk-based and related pharmacotherapy biomarker in mid and late hyperglycemic pregnancy with likely implications of novel therapeutic targets was delineated by clinical pharmacist interventions.